Ticker
    AADI

    Price
    7.21
    Stock movement down
    -0.49 (-6.36%)
    Company name
    Aadi Bioscience Inc
    Exchange
    (NASDAQ
    ,
    Currency
    USD
    )
    Sector
    Healthcare >
    Biotechnology
    Marknadsvärde
    175.89M
    Ent-värde
    66.07M
    Pris/omsättning
    16.01
    Pris/bok
    1.04
    Direktavkastning
    -
    Utdelningens tillväxt
    -
    Tillväxt år
    -
    FCF-utbetalning
    -4.62%
    Efterföljande P/E
    -
    Fremtidig P/E
    -
    PEG
    -
    EPS-tillväxt
    -
    1 års avkastning
    -59.79%
    3 års avkastning
    -58.87%
    5 års avkastning
    -63.58%
    10 års avkastning
    -
    Senast uppdaterad: 2023-03-22
    Aadi Bioscience, Inc. (AADI) Q4 2022 Earnings Call Transcript
    Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q4 2022 Earnings Conference Call March 28, 2023 8:30 AM ETCompany ParticipantsMarcy Graham - Senior Vice President of Investor Relations and...
    28 mars 2023

    iO Charts is a Seeking Alpha partner

    Aadi Bioscience, Inc. 2022 Q4 - Results - Earnings Call Presentation
    The following slide deck was published by Aadi Bioscience, Inc.
    28 mars 2023

    iO Charts is a Seeking Alpha partner

    UTDELNING

    AADI Betalar inte utdelning
    Aadi Bioscience GAAP EPS of -$0.52 beats by $0.19, revenue of $5.23M beats by $0.58M
    Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
    28 mars 2023

    iO Charts is a Seeking Alpha partner

    Aadi Bioscience Q4 2022 Earnings Preview
    Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
    27 mars 2023

    iO Charts is a Seeking Alpha partner

    UTVÄRDERING

    Värderingsvillkor

    Data om värderingsgrad
    Efterföljande P/E-
    Pris till OCF-
    Pris till FCF-
    Pris till EBITDA-
    EV i förhållande till EBITDA-

    Värdering (Försäljning/Bokfört värde)

    Värderingsdata (försäljning/bokfört värde)
    Pris till omsättning16.01
    Pris till eget kapital1.04
    EV i förhållande till försäljning6.01
    Aadi Bioscience: Commercial Stage With Large Market In Label Expansion
    Aadi Bioscience is a commercial stage company with a potential label expansion ahead. Click here to learn why I rate AADI stock a Buy.
    7 mars 2023

    iO Charts is a Seeking Alpha partner

    Aadi Bioscience CEO Brendan Delaney resigns
    Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
    3 mars 2023

    iO Charts is a Seeking Alpha partner

    EKONOMI

    Per aktie

    Data per aktie
    Nuvarande aktiemängd24.40M
    EPS (TTM)-2.94
    FCF per aktie (TTM)-3.84

    Resultaträkning

    Uppgifter om resultaträkningen
    Intäkter (TTM)10.99M
    Bruttovinst (TTM)10.00M
    Rörelseintäkter (TTM)-63.16M
    Nettoresultat (TTM)-62.59M
    EPS (TTM)-2.94
    EPS (1 år framåt)-2.53

    Marginaler

    Marginer-data
    Bruttomarginal (TTM)90.96%
    Rörelsemarginal (TTM)-574.71%
    Vinstmarginal (TTM)-569.57%

    Balans

    Skapa ett gratis konto eller logga in för att komma åt det här diagrammet
    Uppgifter om balansräkningen
    Kontanter134.81M
    Nettofordringar2.26M
    Summa omsättningstillgångar189.86M
    Goodwill0.00
    Immateriella tillgångar0.00
    Materiella anläggningstillgångar0.00
    Summa tillgångar194.10M
    Leverantörsskulder3.92M
    Kortfristig/kortfristig långfristig skuld1.72M
    Summa kortfristiga skulder17.89M
    Summa skulder25.00M
    Eget kapital169.11M
    Materiella anläggningstillgångar netto169.11M

    Kassaflöde

    Skapa ett gratis konto eller logga in för att komma åt det här diagrammet
    Uppgifter om kassaflöde
    Kassaflöde från den löpande verksamheten (TTM)-80.89M
    Investeringar (TTM)676.00K
    Fritt kassaflöde (TTM)-81.57M
    Utbetald utdelning (TTM)3.77M

    Finansiella intäkter

    Skapa ett gratis konto eller logga in för att komma åt det här diagrammet
    Uppgifter om finansiella intäkter
    Avkastning på eget kapital-37.01%
    Avkastning på tillgångar-32.25%
    Avkastning på investerat kapital-36.93%
    Kontantavkastning på investerat kapital-48.13%
    Aadi Bioscience, Inc. (AADI) Q3 2022 Earnings Call Transcript
    Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ETCompany ParticipantsMarcy Graham - Senior Vice President of Investor Relations &...
    9 november 2022

    iO Charts is a Seeking Alpha partner

    Aadi Bioscience GAAP EPS of -$0.68, revenue of $4.24M
    Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
    9 november 2022

    iO Charts is a Seeking Alpha partner

    INFORMATION OM AKTIER

    Aktiediagram

    Uppgifter om aktiekurs
    Öppning7.72
    Dagens högsta7.72
    Daglig låg7.20
    Daglig volym120K
    Den högsta någonsin1485.00
    1 års analytikeruppskattning41.67
    Beta-
    EPS (TTM)-2.94
    Utdelning per aktie-
    Ex-div datum-
    Nästa datum för resultatpresentation28 Mar 2023

    Potential på nackdelen

    Negativa potentiella data
    AADIS&P500
    Nuvarande prisfall från toppnotering-99.51%-17.92%
    Högsta prisfallet-99.51%-56.47%
    Datum för högsta fall22 Mar 20239 Mar 2009
    Genomsnittligt fall från topp-76.27%-11.51%
    Genomsnittlig tid till ny topp72 days13 days
    Maxtid till ny topp1337 days1805 days
    Aadi Bioscience names CEO Neil Desai as executive chairman
    Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
    8 november 2022

    iO Charts is a Seeking Alpha partner

    Aadi Bioscience (AADI) Investor Presentation - Slideshow
    The following slide deck was published by Aadi Bioscience, Inc.
    3 november 2022

    iO Charts is a Seeking Alpha partner

    UPPLYSNINGAR OM FÖRETAG
    AADI (Aadi Bioscience Inc) company logo
    Marknadsvärde
    175.89M
    Kategori av marknadsvärde
    Small-cap
    Beskrivning: __________
    Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
    Anställda
    76
    Webbplats
    https://aadibio.com
    Investerarrelationer
    -
    SEC-inlämningar
    AADI SEC filings
    Verkställande direktör
    Land
    USA
    By
    Typ av aktie
    -
    CCC-status
    -
    Utdelningsfrekvens
    -
    EVENEMANG OCH PRESENTATIONER
    EvenemangPresentationer
    Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors
    Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
    12 oktober 2022

    iO Charts is a Seeking Alpha partner

    Aadi Bioscience (AADI) Presents At Ladenburg Thalmann Healthcare Conference - Slideshow
    The following slide deck was published by Aadi Bioscience, Inc.
    30 september 2022

    iO Charts is a Seeking Alpha partner

    FÖRSTÅ VERKSAMHETEN
    Aadi Bioscience gets $75M private placement financing
    Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
    22 september 2022

    iO Charts is a Seeking Alpha partner

    Aadi Bioscience: Taking mTOR Inhibition To The Next Level
    Aadi Bioscience shares lost half their value since reverse merger with Aerpio Pharmaceuticals. Click here to read why AADI stock is a Buy in my view.
    21 september 2022

    iO Charts is a Seeking Alpha partner

    NYHETER OM FÖRETAGET
    Alla nyheterPressmeddelanden
    Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
    Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, ...
    28 mars 2023
    Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors
    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
    27 mars 2023
    Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer
    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
    26 mars 2023
    Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update
    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
    15 mars 2023
    Aadi Bioscience Announces Leadership Transition
    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announce...
    3 mars 2023
    Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference
    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
    22 februari 2023
    Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting
    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
    17 november 2022
    Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
    Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, ...
    9 november 2022
    Aadi Bioscience Announces Planned Leadership Transition
    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announce...
    8 november 2022
    Aadi Bioscience to Present at Upcoming Investor Conferences
    Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTO...
    3 november 2022
    Nästa sida
    Aadi Bioscience, Inc. (AADI) CEO Neil Desai on Q2 2022 Results - Earnings Call Transcript
    Aadi Bioscience, Inc. (NASDAQ:NASDAQ:AADI) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ETCompany ParticipantsMarcy Graham - SVP of IR and Corporate CommunicationsNeil Desai -...
    10 augusti 2022

    iO Charts is a Seeking Alpha partner

    Aadi Bioscience GAAP EPS of -$0.87, revenue of $3.43M
    Get the latest news and real-time alerts from Aadi Bioscience, Inc. (AADI) stock at Seeking Alpha.
    10 augusti 2022

    iO Charts is a Seeking Alpha partner

    Socialt
    Meny
    Hem
    Portfölj
    Översikt över företaget
    Gröna investeringar
    Kontakta kundtjänst
    Språk EN | HU | NO | SE | DK | FI | ES | DE | NL | FR | IT | PT | PL | RO
    Friskrivning
    iO Charts tar inget ansvar för eventuella fel eller utelämnanden i innehållet på denna webbplats. Informationen på denna webbplats tillhandahålls "i befintligt skick" utan garantier för fullständighet, noggrannhet, användbarhet eller aktualitet. Observera också att alla åtgärder du vidtar baserat på informationen på denna webbplats är helt på egen risk. Denna webbplats är avsedd att användas och får endast användas i informationssyfte. Du bör få oberoende ekonomisk rådgivning från en professionell professionell och oberoende forskning och verifiera allt du ser på webbplatsen.
    © 2021 iO Charts Alla rättigheter förbehållna